Small Cell Lung Cancer – Epidemiology – Epidemiology Dashboard
DRG Epidemiology's coverage of small-cell lung cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of small-cell lung cancer for each country, as well as annualized case counts projected to the national population.
In addition to forecasting incident and prevalent patient populations, the number of drug-treatment opportunities at specific lines of therapy are also forecast across the world.
DRG Epidemiology's small-cell lung cancer forecast will answer the following questions:
How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with small-cell lung cancer per year?
In developing countries, what impact will economic growth and development have on the number of people diagnosed with small-cell lung cancer per year?
How will improvements in survival change the number of first-line drug-treatment opportunities for small-cell lung cancer?
How will decreasing recurrence risk change the number of first-line drug-treatment opportunities for small-cell lung cancer?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of small-cell lung cancer over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graphical depiction of the patient flow between or within different disease states for the countries considered in this report. These patient flow diagrams are provided at the regional level, but may be requested for any specific country or forecast year.
In addition to the total number of cases for each forecast year, DRG Epidemiology also provides at least ten years of forecast data for the following small cell lung cancer subpopulations:
Drug-treatable prevalent cases by metastatic status
Diagnosed extensive first-line drug-treatable population
Diagnosed incident cases by stage distribution status
Diagnosed prevalent cases by drug treatment potential status
Small Cell Lung Cancer - Epidemiology - Epidemiology Dashboard
Introduction
Small Cell Lung Cancer Epidemiology Dashboard
Alexandre Vo Dupuy, Pharm.D., M.Sc.
Alexandre Vo Dupuy, M.Sc., Pharm.D., is a principal epidemiologist at Clarivate. Previously, he worked in the fields of consulting and real-world evidence and at a major pharmaceutical company. He obtained his doctor of pharmacy from Descartes University in Paris and his master’s degree in pharmacoepidemiology from the University of Bordeaux. He has worked in multiple therapy areas, with a focus on cancer epidemiology. He also codeveloped a scenario-based forecast for COVID-19.
